Scarica l'app Stockscreener
4.57
0.87%
-0.04
Precedente Chiudi:
$4.61
Aprire:
$4.61
Volume 24 ore:
231.20K
Relative Volume:
0.55
Capitalizzazione di mercato:
$211.70M
Reddito:
$20.72M
Utile/perdita netta:
$-100.84M
Rapporto P/E:
-1.718
EPS:
-2.66
Flusso di cassa netto:
$-78.56M
1 W Prestazione:
+8.29%
1M Prestazione:
+12.01%
6M Prestazione:
-1.93%
1 anno Prestazione:
-75.32%
Intervallo 1D:
$4.43
$4.61
Intervallo di 1 settimana:
$4.145
$4.7497
Portata 52W:
$2.235
$19.33
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Nome
4 D Molecular Therapeutics Inc
Settore
Industria
Telefono
(510) 505-2680
Indirizzo
5858 HORTON STREET #455, EMERYVILLE
Confronta FDMT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
4.57 | 213.56M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-13 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | Iniziato | Morgan Stanley | Underweight |
| 2024-09-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | Iniziato | Barclays | Overweight |
| 2024-02-07 | Ripresa | Goldman | Buy |
| 2023-10-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-18 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | Iniziato | Chardan Capital Markets | Buy |
| 2023-01-30 | Iniziato | BMO Capital Markets | Outperform |
| 2022-11-18 | Iniziato | H.C. Wainwright | Buy |
| 2022-11-15 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-08-12 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | Iniziato | Jefferies | Buy |
| 2022-01-04 | Iniziato | SVB Leerink | Outperform |
| 2021-01-05 | Iniziato | BofA Securities | Buy |
| 2021-01-05 | Iniziato | Evercore ISI | Outperform |
| 2021-01-05 | Iniziato | Goldman | Neutral |
Mostra tutto
4 D Molecular Therapeutics Inc Borsa (FDMT) Ultime notizie
What drives 4D Molecular Therapeutics Inc. stock priceRapidly expanding wealth - PrintWeekIndia
4D Molecular Therapeutics Inc. Stock Analysis and ForecastTremendous portfolio expansion - PrintWeekIndia
Why 4D Molecular Therapeutics Inc. stock attracts strong analyst attentionLong Term Secure Gain Stocks - Newser
4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists - GlobeNewswire
4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists - GlobeNewswire Inc.
What analysts say about 4D Molecular Therapeutics Inc. stockUnrivaled growth potential - Autocar Professional
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $29.56 Average Price Target from Analysts - Defense World
Is 4D Molecular Therapeutics Inc. a good long term investmentSignificant capital appreciation - jammulinksnews.com
Layoff Tracker: Following Challenges With DMD Therapy, Sarepta Will Cut 500 Employees - BioSpace
Top Stocks for Aggressive Investors Top Growth StocksUnrivaled growth potential - Jammu Links News
Fierce Biotech Layoff Tracker 2025: Sail shrinks crew again; Sarepta lays off 500 staffers - Fierce Biotech
4D Molecular Therapeutics’ Phase 3 Trial: A New Hope for Age-Related Macular Degeneration? - TipRanks
What makes 4D Molecular Therapeutics Inc. stock price move sharplyHigh Return Potential - Newser
How 4D Molecular Therapeutics Inc. stock performs during market volatilityAI Powered Stock Call - Newser
Weiss Ratings Reiterates “Sell (D-)” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
4DMT Announces New Employment Inducement Grants - GlobeNewswire
Late-Stage Biotech 4DMT Grants Significant RSU Package in Latest Strategic Hire - Stock Titan
4D Molecular to layoff about 25% of workforce - MSN
Promising Penny Stocks To Consider In July 2025 - simplywall.st
4D Molecular Therapeutics' (FDMT) Buy Rating Reiterated at Chardan Capital - MarketBeat
Chardan Capital Reiterates “Buy” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics Analyst Ratings: A Comprehensive Analysis - AInvest
4D Molecular Therapeutics Updates Phase 3 Program for Wet AMD - The Globe and Mail
East Bay biotech to slash 25% of jobs after launching 2nd late-stage eye gene therapy study - The Business Journals
4D Molecular Therapeutics Accelerates Wet AMD Trial, Cuts Jobs to Offset Costs - MarketScreener
4DMT Announces Accelerated 4D-150 Phase 3 Development in - GlobeNewswire
4D Molecular to layoff about 25% of workforce (FDMT:NASDAQ) - Seeking Alpha
4D Molecular Therapeutics, Inc.(NasdaqGS:FDMT) dropped from Russell Microcap Growth Index - MarketScreener
Weiss Ratings Reaffirms Sell (E+) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
Cystic Fibrosis Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Oligonucleotides Clinical Trial Pipeline Analysis Demonstrates 280+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - SINA HONG KONG LIMITED
Gene Therapy in Ophthalmology Market Set to Transform Vision Restoration Landscape by 2034 | Says DelveInsight - Barchart.com
Harbor Capital Advisors Inc. Invests $99,000 in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Position Raised by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (D-)” Rating at Weiss Ratings - Defense World
908 Devices’ (MASS) “Sell (D-)” Rating Reiterated at Weiss Ratings - Defense World
Organigram (TSE:OGI) Stock Price Up 2% – Should You Buy? - Defense World
Analysts Issue Forecasts for FDMT FY2026 Earnings - Defense World
Vivani Medical Appoints Anthony Baldor as Chief Financial Officer - The Manila Times
4 D Molecular Therapeutics Inc Azioni (FDMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.97%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):